Piramal Pharma Ltd

Piramal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Piramal Pharma Ltd. reported a consolidated net loss of ₹136.19 crores for Q3 FY26, marking a dramatic deterioration from the ₹3.68 crores profit posted in the same quarter last year. The loss widened 37.26% sequentially from Q2 FY26's ₹99.22 crores, highlighting deepening operational challenges at the ₹20,610 crores market capitalisation pharmaceutical company. The stock tumbled 3.18% to ₹159.15 following the results announcement, reflecting investor concerns over persistent profitability pressures despite modest revenue growth.

Piramal Pharma Ltd’s shares touched a new 52-week low of Rs.148.3 today, marking a significant decline amid a challenging year for the pharmaceutical company. Despite a modest recovery over the past three days, the stock remains under pressure, reflecting ongoing concerns about its financial performance and valuation metrics.

Piramal Pharma Ltd (PPLPHARMA) has witnessed a significant 22.64% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this spike, the stock remains close to its 52-week low, reflecting ongoing bearish sentiment amid subdued price momentum and cautious investor participation.

Piramal Pharma Ltd (PPLPHARMA) has witnessed a notable 13.7% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading close to its 52-week low, the stock has outperformed its sector in recent sessions, reflecting a complex interplay of cautious optimism and bearish undertones among traders.

Piramal Pharma Ltd (PPLPHARMA) has witnessed a notable 12.23% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading close to its 52-week low, the stock has outperformed its sector in recent sessions, reflecting a complex interplay of cautious optimism and bearish undertones among traders.

Piramal Pharma Ltd’s shares touched a fresh 52-week low of Rs.150.15 today, marking a significant decline amid subdued quarterly earnings and ongoing financial pressures. The stock’s performance over the past year has lagged considerably behind the broader market, reflecting challenges in profitability and debt servicing metrics.

Piramal Pharma Ltd’s stock declined to a fresh 52-week low of Rs.154 today, marking a significant drop amid ongoing challenges reflected in its financial performance and market positioning. The stock’s fall contrasts with broader market trends, underscoring persistent pressures within the company’s fundamentals.

Piramal Pharma Ltd’s shares declined to a fresh 52-week low of Rs.160.85 on 20 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed both its sector and the broader market, reflecting a combination of financial pressures and subdued growth metrics.

Piramal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Jan 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 20 January 2026, providing investors with the latest view of the company’s position in the market.

Piramal Pharma Ltd’s shares declined to a fresh 52-week low of Rs.163.5 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed both its sector and the broader market, reflecting a series of financial and performance concerns that have weighed on investor sentiment.

Piramal Pharma Ltd’s shares declined to a fresh 52-week low of Rs.163.7 today, marking a significant milestone in the stock’s ongoing downward trajectory. The stock has been under pressure for several sessions, reflecting a combination of financial and market factors that have weighed on investor sentiment.

Piramal Pharma Ltd has been downgraded from a Sell to a Strong Sell rating as of 8 January 2026, reflecting deteriorating fundamentals and increasingly negative technical indicators. The company’s financial performance has weakened significantly, with key metrics signalling poor profitability and debt servicing challenges. Coupled with bearish technical trends, the downgrade highlights growing investor caution in the Pharmaceuticals & Biotechnology sector.

Piramal Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a deteriorating outlook. The stock’s downgrade to a Strong Sell rating by MarketsMOJO on 8 January 2026 reflects growing bearish sentiment, as price momentum weakens and moving averages confirm downward trends. This analysis explores the technical parameters influencing the stock’s recent performance and what it means for investors navigating the Pharmaceuticals & Biotechnology sector.

Piramal Pharma Ltd (PPLPHARMA) has witnessed a notable 11.2% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest 0.83% gain on the day, the stock’s recent four-day rally and mixed technical indicators suggest a complex interplay of bullish and cautious sentiment among traders.